Lexaria Bioscience (LEXX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexaria Bioscience’s recent animal study reveals promising 12-week results for its DehydraTECH-liraglutide and select CBD formulations in enhancing weight loss, outperforming traditional GLP-1 drugs like semaglutide. The study, which focused on drug delivery innovations, showed accelerated weight loss in the final weeks, highlighting the potential of Lexaria’s technology in diabetes treatment.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.